Pivotal Therapeutics Closes Financing; Receives Over CDN $7.7 Million to Further VASCAZEN® Commercialization

Pivotal Therapeutics Closes Financing;Pivotal Therapeutics Closes Financing; Receives Over CDN $7.7 Million to Further VASCAZEN® Commercialization PR Newswire WOODBRIDGE, Ontario, March 4, 2014 Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies, announced today it has completed its previously announced debt financing issuing a total of 7,744 units at a price of CDN $1,000 per unit for total proceeds of CDN $7,743,580. Pivotal experienced greater demand than anticipated for the Financing and as a result was oversubscribed by 2,744 units resulting in an increase of $2,743,580 over the CDN $5,000,000 previously announced. The financing was led by Crossover Healthcare Fund, LLC, and included Broadfin Capital, LLC and Porter Capital Management Co. "This round of financing, combined with the proceeds from the previous Crossover Healthcare Fund led equity financing, has brought over CDN $10.4 million in new investor capital to Pivotal," stated Mrs. Rachelle MacSweeney, President and COO. "The funds put us in a strong financial position to execute on our near and longer term growth initiatives towards ®commercializing VASCAZEN . We look forward to working with our new financial partners to build value at Pivotal." Each unit will consist of CDN $1,000 of Convertible Promissory Notes (the "Note" or "Notes") and warrants to purchase 1,200 shares of common stock of the Company (the "Warrants").